Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis

H F Dvorak, L F Brown, M Detmar, A M Dvorak, H F Dvorak, L F Brown, M Detmar, A M Dvorak

Abstract

VPF/VEGF is a multifunctional cytokine that contributes to angiogenesis by both direct and indirect mechanisms. On the one hand, VPF/VEGF stimulates the ECs lining nearby microvessels to proliferate, to migrate, and to alter their pattern of gene expression. On the other hand, VPF/VEGF renders these same microvascular ECs hyperpermeable so that they spill plasma proteins into the extravascular space, leading to the clotting of extravasated fibrinogen with deposition of a fibrin gel. Extravascular fibrin serves as a provisional matrix that favors and supports the ingrowth of new blood vessels and other mesenchymal cells that generate mature, vascularized stroma. These same principles apply in tumors, in several examples of non-neoplastic pathology, and in physiological processes that involve angiogenesis and new stroma generation. In all of these examples, microvascular hyperpermeability and the introduction of a provisional, plasma-derived matrix precede and accompany the onset of EC division and new blood vessel formation. It would seem, therefore, that tumors have "borrowed" fundamental mechanisms that developed in multicellular organisms for purposes of tissue defense, renewal, and repair. VPF/VEGF, therefore has taught us something new about angiogenesis; namely, that vascular hyperpermeability and consequent plasma protein extravasation are important, perhaps essential, elements in its generation. However, this finding raises a paradox. While VPF/VEGF induces vascular hyperpermeability, other potent angiogenic factors apparently do not, at least in subtoxic concentrations that are more than sufficient to induce angiogenesis. Nonetheless, wherever angiogenesis has been studied, the newly generated vessels have been found to be hyperpermeable. How, therefore, do angiogenic factors other than VPF/VEGF lead to the formation of new and leaky blood vessels? We do not as yet have a complete answer to this question. One possibility is that at least some angiogenic factors mediate their effect by inducing or stimulating the expression of VPF/VEGF. In fact, there is already one clear example of this. TGF-alpha is a potent angiogenic factor but does not itself increase microvascular permeability. However, TGF-alpha strikingly upregulates VPF/VEGF expression in cultured keratinocytes and is thought to be responsible, at least in part, for the overexpression of VPF/VEGF in psoriasis. Moreover, overexpression of TGF-alpha, along with that of the EGF receptor with which it interacts, is characteristic of many malignant tumors, raising the possibility that TGF-alpha acts to stimulate VPF/VEGF expression in other types of epithelial cells and in this manner induces angiogenesis.(ABSTRACT TRUNCATED AT 400 WORDS)

References

    1. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1323-7
    1. Cancer Res. 1990 Mar 15;50(6):1774-8
    1. Endocrinology. 1990 Aug;127(2):965-7
    1. J Invest Dermatol. 1990 Sep;95(3):333-40
    1. J Biol Chem. 1990 Nov 15;265(32):19461-6
    1. J Exp Med. 1990 Dec 1;172(6):1535-45
    1. Am J Pathol. 1991 Jan;138(1):213-21
    1. Cell. 1991 Feb 22;64(4):841-8
    1. J Biol Chem. 1991 Jun 25;266(18):11947-54
    1. Am J Pathol. 1991 Jun;138(6):1437-50
    1. Cancer Cells. 1991 Mar;3(3):77-85
    1. Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5819-23
    1. Oncogene. 1991 Sep;6(9):1677-83
    1. Anat Embryol (Berl). 1992 Aug;186(3):251-7
    1. Biochem Biophys Res Commun. 1992 Sep 30;187(3):1579-86
    1. Lab Invest. 1992 Nov;67(5):596-607
    1. Cancer Res. 1986 Nov;46(11):5629-32
    1. N Engl J Med. 1986 Dec 25;315(26):1650-9
    1. Lab Invest. 1987 Dec;57(6):673-86
    1. Am J Pathol. 1988 Mar;130(3):455-65
    1. Cancer Res. 1988 Apr 1;48(7):1920-5
    1. J Immunol. 1988 Apr 1;140(7):2340-9
    1. Am J Pathol. 1988 Oct;133(1):95-109
    1. Biochem Biophys Res Commun. 1989 Jun 15;161(2):851-8
    1. Nature. 1992 Oct 29;359(6398):845-8
    1. J Cell Physiol. 1992 Dec;153(3):557-62
    1. J Biol Chem. 1992 Dec 25;267(36):26031-7
    1. Kidney Int. 1992 Dec;42(6):1457-61
    1. Am J Pathol. 1993 Jan;142(1):273-83
    1. Biochem Biophys Res Commun. 1993 Feb 15;190(3):702-8
    1. Arch Biochem Biophys. 1993 Feb 15;301(1):15-20
    1. Cell. 1993 Mar 26;72(6):835-46
    1. J Clin Invest. 1993 May;91(5):2235-43
    1. Cancer Res. 1993 Jun 15;53(12):2912-8
    1. Endocrinology. 1993 Aug;133(2):829-37
    1. Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7533-7
    1. Biochem Biophys Res Commun. 1993 Sep 15;195(2):1005-10
    1. Ann N Y Acad Sci. 1992 Dec 4;667:101-11
    1. Cancer Res. 1993 Oct 1;53(19):4727-35
    1. Am J Pathol. 1993 Nov;143(5):1255-62
    1. Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24
    1. Physiol Rev. 1994 Jan;74(1):163-219
    1. J Biol Chem. 1994 Feb 11;269(6):4355-9
    1. J Invest Dermatol. 1984 May;82(5):465-70
    1. Science. 1985 Mar 1;227(4690):1059-61
    1. Adv Cancer Res. 1985;44:139-266
    1. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9026-30
    1. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9267-71
    1. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1568-75
    1. J Exp Med. 1991 Nov 1;174(5):1275-8
    1. Biochem Biophys Res Commun. 1991 Oct 31;180(2):572-8
    1. Biochem Biophys Res Commun. 1991 Dec 16;181(2):902-6
    1. J Cell Biochem. 1991 Nov;47(3):211-8
    1. Mol Endocrinol. 1991 Dec;5(12):1806-14
    1. Science. 1992 Feb 21;255(5047):989-91
    1. J Surg Res. 1992 Jan;52(1):50-8
    1. Mol Biol Cell. 1992 Feb;3(2):211-20
    1. Endocr Rev. 1992 Feb;13(1):18-32
    1. Development. 1992 Feb;114(2):521-32
    1. J Biol Chem. 1992 Jun 5;267(16):10931-4
    1. Br J Dermatol. 1992 May;126(5):436-45
    1. Biol Cell. 1991;73(1):1-6
    1. EXS. 1992;61:255-60
    1. Cancer Res. 1992 Sep 1;52(17):4821-3
    1. J Exp Med. 1992 Nov 1;176(5):1375-9
    1. J Reprod Fertil. 1993 Nov;99(2):609-15
    1. J Biol Chem. 1994 Mar 4;269(9):6271-4
    1. Biochem Biophys Res Commun. 1994 Feb 28;199(1):380-6
    1. J Immunol. 1994 Apr 15;152(8):4149-56
    1. Mol Biol Cell. 1993 Dec;4(12):1317-26
    1. J Exp Med. 1994 Jul 1;180(1):341-6
    1. J Clin Endocrinol Metab. 1994 Jul;79(1):316-22
    1. Circulation. 1994 Aug;90(2):649-52
    1. J Exp Med. 1994 Sep 1;180(3):1141-6
    1. Placenta. 1994 Jun;15(4):341-53
    1. Biol Reprod. 1994 Sep;51(3):524-30
    1. Cancer Res. 1995 Jan 15;55(2):360-8
    1. Cancer Res. 1995 Jan 15;55(2):376-85
    1. Hum Pathol. 1995 Jan;26(1):86-91
    1. J Immunol. 1995 Mar 15;154(6):2801-7
    1. Nature. 1992 Oct 29;359(6398):843-5
    1. Acta Derm Venereol. 1972;52(4):295-7
    1. Adv Cancer Res. 1972;16:181-234
    1. J Pathol. 1972 Jul;107(3):157-66
    1. J Invest Dermatol. 1974 May;62(5):493-502
    1. J Immunol. 1975 Jan;114(1 Pt 2):377-87
    1. Am J Anat. 1975 Mar;142(3):295-317
    1. J Immunol. 1979 Jan;122(1):166-74
    1. J Natl Cancer Inst. 1979 Jun;62(6):1459-72
    1. J Invest Dermatol. 1980 Oct;75(4):302-5
    1. Science. 1981 May 22;212(4497):923-4
    1. Nihon Sanka Fujinka Gakkai Zasshi. 1980 Jul;32(7):859-67
    1. Science. 1983 Feb 25;219(4587):983-5
    1. J Am Acad Dermatol. 1983 Feb;8(2):193-9
    1. Cancer Res. 1983 Sep;43(9):4434-42
    1. Cancer Metastasis Rev. 1983;2(1):41-73
    1. Cancer Res. 1984 Aug;44(8):3348-54
    1. Cancer Res. 1984 Sep;44(9):3719-23
    1. J Natl Cancer Inst. 1984 Nov;73(5):1195-205
    1. Cancer. 1986 Feb 1;57(3):461-4
    1. J Dairy Sci. 1986 Mar;69(3):927-43
    1. Microvasc Res. 1986 May;31(3):288-305
    1. J Invest Dermatol. 1986 May;86(5):577-81
    1. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7311-5
    1. J Clin Invest. 1989 Nov;84(5):1470-8
    1. EMBO J. 1989 Dec 1;8(12):3801-6
    1. J Biol Chem. 1989 Nov 25;264(33):20017-24
    1. Science. 1989 Dec 8;246(4935):1306-9
    1. J Cell Biol. 1989 Dec;109(6 Pt 1):3137-45
    1. Biochem Biophys Res Commun. 1989 Dec 29;165(3):1198-206

Source: PubMed

3
Abonnieren